Company Overview
Sensus Healthcare, Inc. operates as a medical device company that manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 +; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, such as applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos, as well as provide operational healthcare services for dermatology clinics. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. The company was incorporated in 2010 and is based in Boca Raton, Florida.
Why Investors Should Care
Revenue has grown at a 11.6% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $27.48M (-34.3% YoY); net profit $-7.72M.
- Trailing 12 Months Year-on-year growth — revenue -68.7%, earnings -216.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 11.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 11.55% |
| 1 Year: | -68.70% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -216.13% |
Stock Price Performance
| 1 Year: | -7.60% |
| 6 Months: | -27.36% |
| 3 Months: | +17.47% |
| 1 Month: | +2.93% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)48.16 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 11.6% over 5 years.
CONS
- Trading 40.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SRTS Sensus Healthcare, Inc. PHARMA | 3.16 | -3.36 | $52.02M | 0.00% | -21.33% | -34.83% | 11.55% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.66M | 9.24M | 8.84M | - | 8.34M | 7.32M | 6.88M | 4.94M | 3.39M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.99M | 4.41M | 4.17M | 3.04M | 2.40M |
| Gross Profit | 1.55M | 1.42M | 1.93M | 2.32M | 2.25M | 2.85M | 3.41M | 3.22M | 3.94M | 3.94M | 4.17M | 3.32M | 4.94M | 3.84M | 709.00K | 640.00K | 672.00K | 1.59M | 3.35M | 3.20M | 7.15M | 8.26M | 5.87M | 1.62M | 2.62M | 1.99M | 6.66M | 5.42M | 5.24M | - | 4.35M | 2.90M | 2.71M | 1.90M | 991.00K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.00M | 4.85M | 5.28M | 5.04M | 5.35M |
| Operating Income | -87.71K | -74.31K | 9.59K | -348.77K | -44.22K | -1.59M | -765.83K | -965.43K | -1.11M | -498.73K | -423.36K | -2.19M | 45.48K | -805.13K | -3.64M | -2.57M | -2.28M | -1.11M | -279.00K | 195.00K | 3.93M | 4.57M | 2.16M | -2.94M | -1.13M | -1.90M | 2.89M | 1.98M | 1.50M | - | -2.65M | -1.94M | -2.57M | -3.15M | -4.36M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.50M | -1.78M | -2.41M | -2.98M | -4.20M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.46M | -1.76M | -2.41M | -2.99M | -4.23M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 110.00K | -723.00K | -1.47M | 174.00K | -1.61M |
| Net Income | -88.75K | -78.07K | 2.08K | -351.30K | -30.41K | -1.57M | -764.11K | -965.69K | -1.13M | -540.65K | -458.11K | -2.12M | 112.31K | -730.39K | -3.59M | -2.57M | -1.69M | -1.11M | -279.00K | 195.00K | 16.06M | 3.52M | 1.83M | -1.89M | -380.00K | -1.45M | 2.27M | 1.61M | 1.22M | - | -2.57M | -1.04M | -943.00K | -3.17M | -2.63M |
| Diluted EPS | - | - | 0.00 | - | - | -0.12 | - | - | - | -0.04 | - | - | 0.01 | - | - | -0.16 | -0.10 | -0.07 | -0.02 | 0.01 | 0.97 | 0.21 | 0.11 | -0.12 | -0.02 | -0.09 | 0.14 | 0.10 | 0.07 | - | -0.16 | -0.06 | -0.06 | -0.19 | -0.16 |
| R&D Expense | 334.12K | 358.49K | 293.40K | 413.63K | 389.76K | 1.14M | 1.16M | 1.50M | 1.50M | 1.57M | 1.71M | 1.97M | 1.93M | 1.57M | 1.23M | 1.15M | 941.00K | 661.00K | 925.00K | 744.00K | 728.00K | 827.00K | 746.00K | 1.10M | 822.00K | 1.08M | 926.00K | 866.00K | 863.00K | - | 2.61M | 1.47M | 1.82M | - | 1.59M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.27M | 14.81M | 20.59M | 26.43M | 27.26M | 9.58M | - | 44.53M | 24.41M | 41.81M | 27.48M |
| Cost of Revenue | - | - | - | - | - | - | - | 14.90M | 10.35M | 17.38M | 15.62M |
| Gross Profit | 6.58M | 9.85M | 13.80M | 16.91M | 17.56M | 5.25M | - | 29.63M | 14.06M | 24.43M | 11.87M |
| Operating Expenses | - | - | - | - | - | - | - | 14.80M | 14.44M | 16.34M | 22.17M |
| Operating Income | -221.26K | -363.12K | -3.72M | -2.01M | -1.97M | -8.23M | - | 14.83M | -382.00K | 8.09M | -10.31M |
| EBITDA | - | - | - | - | - | - | - | 15.34M | 79.00K | 8.52M | -9.68M |
| Interest Expense | - | - | - | - | - | - | 2.00K | 2.00K | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | 27.99M | 652.00K | 9.02M | -9.62M |
| Tax Provision | - | - | - | - | - | - | - | 3.75M | 167.00K | 2.38M | -1.91M |
| Net Income | -237.27K | -346.45K | -3.71M | -2.02M | -1.70M | -6.84M | - | 24.24M | 485.00K | 6.65M | -7.72M |
| Diluted EPS | - | - | - | - | - | -0.42 | - | 1.46 | 0.03 | 0.41 | -0.47 |
| R&D Expense | 1.47M | 1.82M | 5.49M | 6.26M | 6.42M | 4.16M | 3.44M | 3.46M | 3.68M | 4.22M | 7.78M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 9.64M | 18.95M | 18.84M | 33.25M | 36.92M | 28.01M | - | 56.73M | 53.71M | 62.16M | 53.04M |
| Current Assets | - | - | - | - | - | - | - | - | 53.24M | 49.53M | 56.74M | 45.89M |
| Cash & Equivalents | 4.54M | 5.07M | 5.04M | 10.09M | 12.48M | 8.10M | 14.91M | - | 25.52M | 23.15M | 22.06M | 22.08M |
| Inventory | - | - | - | - | - | - | - | - | 3.50M | 11.86M | 10.10M | 14.56M |
| Receivables | - | - | - | - | - | - | - | - | 17.30M | 10.64M | 19.73M | 6.04M |
| Total Liabilities | - | 3.71M | 3.67M | 7.15M | 6.79M | 8.92M | 6.51M | - | 8.67M | 4.87M | 6.34M | 4.94M |
| Current Liabilities | - | 3.67M | 3.66M | 4.87M | 6.02M | 6.47M | 4.86M | - | 7.70M | 4.21M | 5.88M | 4.72M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | 1.02M | 783.00K | 602.00K | 471.00K |
| Total Equity | 4.14M | 5.92M | 15.27M | 11.68M | 26.46M | 28.00M | 21.50M | - | 48.07M | 48.84M | 55.83M | 48.10M |
| Shares Outstanding | - | - | - | - | - | - | - | - | 16.90M | 16.91M | 17.04M | 17.06M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | -2.11M | -434.00K | - | -1.41M | -2.15M | -831.00K | 528.00K |
| Investing Cash Flow | - | - | - | -2.64M | -4.90M | 7.03M | - | 14.84M | -187.00K | -276.00K | -196.00K |
| Financing Cash Flow | - | - | - | 13.60M | 2.62M | 211.00K | - | -2.43M | -40.00K | 15.00K | -305.00K |
| Capital Expenditure | -196.19K | -286.00K | -287.59K | -854.83K | -400.59K | -359.00K | - | -159.00K | -229.00K | -276.00K | -196.00K |
| Free Cash Flow | - | - | - | - | -2.51M | -793.00K | - | -1.57M | -2.37M | -1.11M | 332.00K |
| Net Change in Cash | - | - | - | - | - | - | - | 11.00M | -2.37M | -1.09M | 27.00K |
| Share Buybacks | - | - | - | - | - | - | - | 3.00M | 27.00K | - | 300.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 64.1% | 66.5% | 67.0% | 64.0% | 64.4% | 54.8% | - | 66.5% | 57.6% | 58.4% | 43.2% |
| Operating Margin % | -2.2% | -2.5% | -18.1% | -7.6% | -7.2% | -86.0% | - | 33.3% | -1.6% | 19.4% | -37.5% |
| Net Margin % | -2.3% | -2.3% | -18.0% | -7.7% | -6.2% | -71.4% | - | 54.4% | 2.0% | 15.9% | -28.1% |
| ROE % | -4.0% | -2.3% | -31.8% | -7.6% | -6.1% | -31.8% | - | 50.4% | 1.0% | 11.9% | -16.0% |
| ROCE % | -3.7% | -2.4% | -26.6% | -7.4% | -6.5% | -35.6% | - | 30.2% | -0.8% | 14.4% | -21.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Pacific Ridge Capital Partners, LLC | 4.80% | 789.67K | $2.41M |
| 2 | Vanguard Capital Management LLC | 4.01% | 660.40K | $2.01M |
| 3 | Dimensional Fund Advisors LP | 1.92% | 316.12K | $964.17K |
| 4 | Divisadero Street Capital Management, LP | 1.69% | 278.49K | $849.38K |
| 5 | Renaissance Technologies, LLC | 1.47% | 242.33K | $739.12K |
| 6 | Geode Capital Management, LLC | 0.94% | 154.15K | $470.16K |
| 7 | UBS Group AG | 0.93% | 152.57K | $465.35K |
| 8 | Sachetta, LLC | 0.92% | 152.01K | $463.62K |
| 9 | Greenline Wealth Management LLC | 0.78% | 128.77K | $392.76K |
| 10 | North Star Investment Management Corp | 0.76% | 125.59K | $383.04K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SRTS
Sensus Healthcare Stock Price Forecast. Should You Buy SRTS? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE1BVW5pZ1Y2UlV1NEdadjNQZmhiNnJEYVlVNzN1S3Z4UVA4Ym54MVNibTlQSk92bXV6Q00xTzNtUUdiQ0h0Sk5vWQ?oc=5" target="_blank">Sensus Healthcare Stock Price Forecast. Should You Buy SRTS?</a> …
How The Sensus Healthcare (SRTS) Story Is Shifting With New Targets And 2026 Reimbursement Changes - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxQWm5MX0ZPd0R4RFhKZDRiX3dVdjlGMllwQ3YyRE5VZ0pfV1RMMHJNcGVNUURMdmxoYktiZGNHanBrWm9sME1XeFNJUVk5bEJqS0VDSkxRS3FZcGZFLS1MdG8tUmpGZU9WbjVCLTZwZWFxQlJQSDNrSzF4UmptdTF4WnRZR1VjdzJzRFBFSk…
CMS Proposes 26% Increase in Sensus Hospital Delivery Code - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQdm9FdUFSN0dZWlhPTTd5VUVaZi12MUlaNDhmM0FHMkxidnpiV0tucEZkSTdPSzlHb3hPckpnOG9Md1UwaEVMdXFQeUd6RF9GNFdQX2l1SFAtS2hYRXZsMmItWjNHZVd2R1FaeGV5cXN3ZG92YlRQTklraFpqeUhCanlOSGdSa2QtZVN3Nz…
SENSUS HEALTHCARE ($SRTS) Releases Q2 2026 Earnings - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxNS2VkZzNHVHA1YnlnbFhibTlQYVJ5SERVSEZ3anpuam9rY1lXRlROUGNRRW9lOWZZRlItWFBzSENZdjRTX1k3R2hoVk5xcHpWMHN4dFFoYlRtY2ZDaG9VeGJCVmQtNW9JM2ItUjYzZm12Uk9YUDdaSm54QmNPT1lSNkJTRzlrV19oaFhLbA…
Sensus Healthcare's Eric Sachetta Acquires 20% More Stock - simplywall.st
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxPWDNqbTg1dzV2SS13eE1DczFNZWFMZ25Wa0d1ZW5XYm1rbDNBV0dVNGM5QUpzS1B4dDByVHhaMFZXbm5nS3oyZFFIaTFfSGpiNDJ1YTVTVVlkOW1mY0tWbGtlUklxYzRwLTU4a1ZMWGwweGFyV1hqYmNkdnZIb0cyY2lyendnX1B3R0xFS1…
Sensus Healthcare's Eric Sachetta Acquires 20% More Stock - Sahm
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxPVGN1aFFZUmw1eUpid2JITlR5ZW5XaHR1U0tHUllmaGtYNGJMT3BzendSMFJITzRCUEQ5V0F5TTJoV2xaVHpkeUQ5UkdzUWQ2UV9SeGxNNDFNLTRuZlc0b0g1UUR6THFnN3A0UHhUcVZfYlE2VExocFVIb3JyUmh6OWxmejNCSmVWa0gxMX…
SRTS — Frequently Asked Questions
What is the current share price of Sensus Healthcare, Inc. (SRTS)?
As of 2026-09-19 21:16 PDT, Sensus Healthcare, Inc. (SRTS) trades at $3.16 on NasdaqCM. Its 52-week range is $2.69 to $5.30.
What is the market capitalisation of SRTS?
Sensus Healthcare, Inc. (SRTS) has a market capitalisation of $52.02M on NasdaqCM.
What is the P/E ratio of SRTS?
SRTS trades at a trailing price-to-earnings (P/E) ratio of -3.36. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.36.
What is the return on equity (ROE) of SRTS?
SRTS has a return on equity (ROE) of -34.83%. Its return on capital employed (ROCE) is -21.33%.
Is SRTS a good stock to buy?
This page provides a data-driven analysis of Sensus Healthcare, Inc. (SRTS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.